Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

Phase 3

Completed

Conditions: Dyslipidemia
Type II Diabetes

Interventions: Drug: YH14755
Drug: Metformin
Drug: Rosuvastatin

First Posted Date: 2015-10-26

Last Posted Date: 2018-10-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 249

Registration Number: NCT02586129

Locations: 🇰🇷
Seoul National Universitiy Bundang Hospital, Seongnam-Si, Gyeonggi-Do, Korea, Republic of

A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.

Phase 2

Completed

Conditions: Chronic Periodontitis

Interventions: Drug: YH23537 1000mg/day
Drug: YH23537 2000mg/day
Drug: YH23537 3000mg/day
Drug: placebo

First Posted Date: 2015-10-23

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 275

Registration Number: NCT02585596

Locations: 🇰🇷
Incheol Rhyu, Seoul, Korea, Republic of

A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia

Phase 2

Terminated

Conditions: Functional Dyspepsia

Interventions: Drug: YH12852 0.1 mg
Drug: YH12852 0.25 mg
Drug: YH12852 0.5 mg
Drug: Placebo

First Posted Date: 2015-10-05

Last Posted Date: 2022-01-13

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 12

Registration Number: NCT02567578

Locations: 🇰🇷
Samsung seoul hospital, Seoul, Korea, Republic of

Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation

Phase 1

Completed

Conditions: Functional Constipation

Interventions: Drug: YH12852 IR 0.1mg
Drug: YH12852 DR1 2mg
Drug: YH12852 IR 0.05mg
Drug: YH12852 IR 0.5mg
Drug: YH12852 IR 2mg
Drug: YH12852 IR 0.3mg
Drug: YH12852 IR 1mg
Drug: Placebo
Drug: YH12852 IR 3mg
Drug: YH12852 DR1 0.5mg
Drug: YH12852 DR1 1mg
Drug: YH12852 DR1 4mg
Drug: Prucalopride 2mg
Drug: YH12852 DR2 8mg

First Posted Date: 2015-09-02

Last Posted Date: 2016-10-31

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 120

Registration Number: NCT02538367

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: YH22162
Drug: Telmisartan/Amlodipine 80/5 mg (FDC)
Drug: Chlorthalidone 25mg

First Posted Date: 2015-07-14

Last Posted Date: 2015-09-25

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 180

Registration Number: NCT02496910

Locations: 🇰🇷
Chonbuk National University Hospital, Chunju, Korea, Republic of

Clinical Trial of YH14618 in Patients With Degenerative Disc Disease

Phase 2

Completed

Conditions: Disc Degenerative Disease

Interventions: Drug: Placebo
Drug: YH14618

First Posted Date: 2014-12-19

Last Posted Date: 2016-11-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 326

Registration Number: NCT02320019

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy Male Volunteer

Interventions: Drug: Telmisartan
Drug: Amlodipine
Drug: Rosuvastatin

First Posted Date: 2014-09-08

Last Posted Date: 2015-02-18

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 60

Registration Number: NCT02233218

Locations: 🇰🇷
Dong-A university hospital, Pusan, Korea, Republic of

The Exploration for Pharmacodynamics and Pharmacokinetics of YH4808 New Formulation in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: YH4808 NF 100
Drug: YH4808 OF 200
Drug: YH4808 NF 400
Drug: YH4808 NF 200

First Posted Date: 2014-06-27

Last Posted Date: 2022-01-13

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 82

Registration Number: NCT02176668

Locations: 🇰🇷
Yonsei Medical Center Severance Hospital Clinical Trials Center, Seoul, Korea, Republic of

Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Amlodipine
Drug: Chlorthalidone

First Posted Date: 2014-06-02

Last Posted Date: 2014-11-19

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 66

Registration Number: NCT02152969

Locations: 🇰🇷
The Catholic University of Korea Seoul St.Mary's Hospital, Seoul, Korea, Republic of

Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rosuvastatin, Metformin, YH14755
Drug: YH14755

First Posted Date: 2014-04-29

Last Posted Date: 2014-10-09

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 56

Registration Number: NCT02125227

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy